KOC
ATOS icon

Koss-Olinger Consulting’s Atossa Therapeutics ATOS Stock Holding History

Koss-Olinger Consulting’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-800
Closed -$11K – 309
2024
Q4 		$11K Sell
800
-200
-20% -$3.9K ﹤0.01% 185
2024
Q3 		$23K Hold
1,000
– – ﹤0.01% 273
2024
Q2 		$18K Buy
+1,000
New +$22.1K ﹤0.01% 264

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Koss-Olinger Consulting's ATOS Position: Q1 2025 in Review

Koss-Olinger Consulting sold out of Atossa Therapeutics (ATOS) in Q1 2025, closing a stake of 800 shares — an estimated $11K sold.

Koss-Olinger Consulting first reported a position in ATOS in Q2 2024 and held it in 3 quarters. The position peaked at $23K in Q3 2024. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2025.

  • Koss-Olinger Consulting reported no remaining Atossa Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Koss-Olinger Consulting sold 800 Atossa Therapeutics shares in Q1 2025, an estimated $11K.
  • Koss-Olinger Consulting first reported a position in Atossa Therapeutics in Q2 2024 and held it in 3 quarters.
  • Koss-Olinger Consulting's Atossa Therapeutics position peaked at $23K in Q3 2024.
  • 83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2025.

Based on Koss-Olinger Consulting's 13F filing for Q1 2025, filed 12 May 2025.